PMC:7600245 / 37638-38432 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T140","span":{"begin":133,"end":136},"obj":"Body_part"},{"id":"T141","span":{"begin":139,"end":151},"obj":"Body_part"},{"id":"T142","span":{"begin":160,"end":169},"obj":"Body_part"},{"id":"T143","span":{"begin":229,"end":234},"obj":"Body_part"},{"id":"T144","span":{"begin":258,"end":261},"obj":"Body_part"},{"id":"T145","span":{"begin":273,"end":278},"obj":"Body_part"},{"id":"T146","span":{"begin":357,"end":360},"obj":"Body_part"},{"id":"T147","span":{"begin":753,"end":760},"obj":"Body_part"}],"attributes":[{"id":"A140","pred":"fma_id","subj":"T140","obj":"http://purl.org/sig/ont/fma/fma278683"},{"id":"A141","pred":"fma_id","subj":"T141","obj":"http://purl.org/sig/ont/fma/fma62925"},{"id":"A142","pred":"fma_id","subj":"T142","obj":"http://purl.org/sig/ont/fma/fma241981"},{"id":"A143","pred":"fma_id","subj":"T143","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A144","pred":"fma_id","subj":"T144","obj":"http://purl.org/sig/ont/fma/fma278683"},{"id":"A145","pred":"fma_id","subj":"T145","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A146","pred":"fma_id","subj":"T146","obj":"http://purl.org/sig/ont/fma/fma278683"},{"id":"A147","pred":"fma_id","subj":"T147","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"It is a small, synthetic, azabicyclic molecule (Figure S4) that exhibits antiretroviral activity by blocking the interaction between HIV-1 glycoprotein 120 and chemokine receptor 5 (C-C motif receptor 5), on human CD4-presenting cells, that is necessary for HIV-1 to enter cells [116]. The drug was approved by the U.S. FDA in 2007 as an oral treatment for HIV-1. The drug is currently being evaluated in three clinical trials (NCT04441385, NCT04435522, and NCT04475991) for COVID-19 treatment. Recently, it was shown that maraviroc may act as a potential inhibitor of Mpro [117]. However, it appears that it is more realistic to assume that the drug is a viral entry inhibitor and potentially acts by blocking the interaction between the viral spike S protein and the host ACE2 receptor [118]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T140","span":{"begin":475,"end":483},"obj":"Disease"}],"attributes":[{"id":"A140","pred":"mondo_id","subj":"T140","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"It is a small, synthetic, azabicyclic molecule (Figure S4) that exhibits antiretroviral activity by blocking the interaction between HIV-1 glycoprotein 120 and chemokine receptor 5 (C-C motif receptor 5), on human CD4-presenting cells, that is necessary for HIV-1 to enter cells [116]. The drug was approved by the U.S. FDA in 2007 as an oral treatment for HIV-1. The drug is currently being evaluated in three clinical trials (NCT04441385, NCT04435522, and NCT04475991) for COVID-19 treatment. Recently, it was shown that maraviroc may act as a potential inhibitor of Mpro [117]. However, it appears that it is more realistic to assume that the drug is a viral entry inhibitor and potentially acts by blocking the interaction between the viral spike S protein and the host ACE2 receptor [118]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T340","span":{"begin":6,"end":7},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T341","span":{"begin":88,"end":96},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T342","span":{"begin":208,"end":213},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T343","span":{"begin":214,"end":217},"obj":"http://purl.obolibrary.org/obo/PR_000001004"},{"id":"T344","span":{"begin":229,"end":234},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T345","span":{"begin":273,"end":278},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T346","span":{"begin":280,"end":283},"obj":"http://purl.obolibrary.org/obo/CLO_0001046"},{"id":"T347","span":{"begin":544,"end":545},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T348","span":{"begin":654,"end":655},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"It is a small, synthetic, azabicyclic molecule (Figure S4) that exhibits antiretroviral activity by blocking the interaction between HIV-1 glycoprotein 120 and chemokine receptor 5 (C-C motif receptor 5), on human CD4-presenting cells, that is necessary for HIV-1 to enter cells [116]. The drug was approved by the U.S. FDA in 2007 as an oral treatment for HIV-1. The drug is currently being evaluated in three clinical trials (NCT04441385, NCT04435522, and NCT04475991) for COVID-19 treatment. Recently, it was shown that maraviroc may act as a potential inhibitor of Mpro [117]. However, it appears that it is more realistic to assume that the drug is a viral entry inhibitor and potentially acts by blocking the interaction between the viral spike S protein and the host ACE2 receptor [118]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T573","span":{"begin":38,"end":46},"obj":"Chemical"},{"id":"T574","span":{"begin":55,"end":57},"obj":"Chemical"},{"id":"T575","span":{"begin":139,"end":151},"obj":"Chemical"},{"id":"T576","span":{"begin":290,"end":294},"obj":"Chemical"},{"id":"T577","span":{"begin":368,"end":372},"obj":"Chemical"},{"id":"T578","span":{"begin":523,"end":532},"obj":"Chemical"},{"id":"T579","span":{"begin":556,"end":565},"obj":"Chemical"},{"id":"T580","span":{"begin":646,"end":650},"obj":"Chemical"},{"id":"T581","span":{"begin":668,"end":677},"obj":"Chemical"},{"id":"T582","span":{"begin":753,"end":760},"obj":"Chemical"}],"attributes":[{"id":"A573","pred":"chebi_id","subj":"T573","obj":"http://purl.obolibrary.org/obo/CHEBI_25367"},{"id":"A574","pred":"chebi_id","subj":"T574","obj":"http://purl.obolibrary.org/obo/CHEBI_29401"},{"id":"A575","pred":"chebi_id","subj":"T575","obj":"http://purl.obolibrary.org/obo/CHEBI_17089"},{"id":"A576","pred":"chebi_id","subj":"T576","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A577","pred":"chebi_id","subj":"T577","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A578","pred":"chebi_id","subj":"T578","obj":"http://purl.obolibrary.org/obo/CHEBI_63608"},{"id":"A579","pred":"chebi_id","subj":"T579","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A580","pred":"chebi_id","subj":"T580","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A581","pred":"chebi_id","subj":"T581","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A582","pred":"chebi_id","subj":"T582","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"It is a small, synthetic, azabicyclic molecule (Figure S4) that exhibits antiretroviral activity by blocking the interaction between HIV-1 glycoprotein 120 and chemokine receptor 5 (C-C motif receptor 5), on human CD4-presenting cells, that is necessary for HIV-1 to enter cells [116]. The drug was approved by the U.S. FDA in 2007 as an oral treatment for HIV-1. The drug is currently being evaluated in three clinical trials (NCT04441385, NCT04435522, and NCT04475991) for COVID-19 treatment. Recently, it was shown that maraviroc may act as a potential inhibitor of Mpro [117]. However, it appears that it is more realistic to assume that the drug is a viral entry inhibitor and potentially acts by blocking the interaction between the viral spike S protein and the host ACE2 receptor [118]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T280","span":{"begin":0,"end":285},"obj":"Sentence"},{"id":"T281","span":{"begin":286,"end":319},"obj":"Sentence"},{"id":"T282","span":{"begin":320,"end":363},"obj":"Sentence"},{"id":"T283","span":{"begin":364,"end":494},"obj":"Sentence"},{"id":"T284","span":{"begin":495,"end":580},"obj":"Sentence"},{"id":"T285","span":{"begin":581,"end":794},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"It is a small, synthetic, azabicyclic molecule (Figure S4) that exhibits antiretroviral activity by blocking the interaction between HIV-1 glycoprotein 120 and chemokine receptor 5 (C-C motif receptor 5), on human CD4-presenting cells, that is necessary for HIV-1 to enter cells [116]. The drug was approved by the U.S. FDA in 2007 as an oral treatment for HIV-1. The drug is currently being evaluated in three clinical trials (NCT04441385, NCT04435522, and NCT04475991) for COVID-19 treatment. Recently, it was shown that maraviroc may act as a potential inhibitor of Mpro [117]. However, it appears that it is more realistic to assume that the drug is a viral entry inhibitor and potentially acts by blocking the interaction between the viral spike S protein and the host ACE2 receptor [118]."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1132","span":{"begin":160,"end":180},"obj":"Gene"},{"id":"1133","span":{"begin":214,"end":217},"obj":"Gene"},{"id":"1134","span":{"begin":774,"end":778},"obj":"Gene"},{"id":"1135","span":{"begin":569,"end":573},"obj":"Gene"},{"id":"1136","span":{"begin":133,"end":138},"obj":"Species"},{"id":"1137","span":{"begin":208,"end":213},"obj":"Species"},{"id":"1138","span":{"begin":258,"end":263},"obj":"Species"},{"id":"1139","span":{"begin":357,"end":362},"obj":"Species"},{"id":"1140","span":{"begin":523,"end":532},"obj":"Chemical"},{"id":"1141","span":{"begin":475,"end":483},"obj":"Disease"}],"attributes":[{"id":"A1132","pred":"tao:has_database_id","subj":"1132","obj":"Gene:1234"},{"id":"A1133","pred":"tao:has_database_id","subj":"1133","obj":"Gene:920"},{"id":"A1134","pred":"tao:has_database_id","subj":"1134","obj":"Gene:59272"},{"id":"A1135","pred":"tao:has_database_id","subj":"1135","obj":"Gene:8673700"},{"id":"A1136","pred":"tao:has_database_id","subj":"1136","obj":"Tax:11676"},{"id":"A1137","pred":"tao:has_database_id","subj":"1137","obj":"Tax:9606"},{"id":"A1138","pred":"tao:has_database_id","subj":"1138","obj":"Tax:11676"},{"id":"A1139","pred":"tao:has_database_id","subj":"1139","obj":"Tax:11676"},{"id":"A1140","pred":"tao:has_database_id","subj":"1140","obj":"MESH:D000077592"},{"id":"A1141","pred":"tao:has_database_id","subj":"1141","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"It is a small, synthetic, azabicyclic molecule (Figure S4) that exhibits antiretroviral activity by blocking the interaction between HIV-1 glycoprotein 120 and chemokine receptor 5 (C-C motif receptor 5), on human CD4-presenting cells, that is necessary for HIV-1 to enter cells [116]. The drug was approved by the U.S. FDA in 2007 as an oral treatment for HIV-1. The drug is currently being evaluated in three clinical trials (NCT04441385, NCT04435522, and NCT04475991) for COVID-19 treatment. Recently, it was shown that maraviroc may act as a potential inhibitor of Mpro [117]. However, it appears that it is more realistic to assume that the drug is a viral entry inhibitor and potentially acts by blocking the interaction between the viral spike S protein and the host ACE2 receptor [118]."}